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Abstract 
 
Lymphoblastoid cell line (LCL) collections offer a vast source of biological data of various diseases stored 
in biobanks. Even though LCLs have been used as a conducive surrogate in vitro cell model to study 
various diseases, it has been shown that they cannot recapitulate all the regulatory properties of a disorder 
specific primary tissue, constraining the utility of the collections. The rise of induced pluripotent stem cell 
(iPSC) technology has offered a novel strategy for repurposing the abundant LCL collections for 
regenerative medicine, drug discovery and disease modeling. However, the cell-type-specific 
reprogramming events in LCLs are not understood, hindering the development of a more efficient and 
reliable reprogramming method for these cell lines. To systematically study the endogenous events taking 
place during the reprogramming process, the CRISPR/Cas mediated gene activation (CRISPRa) platform 
has been harnessed in fibroblasts. 
 
This thesis work aimed to establish the novel CRISPRa mediated reprogramming method for the first time 
in biobanked LCLs, obtained from the Psychiatric Family Collections of THL Biobank. The method relies 
on the activation of the endogenous pluripotency factors with CRISPR activators, which results in the 
induction of the reprogramming process. The screening of different factor combinations revealed that the 
successful reprogramming of LCLs seems to require the targeting of the EEA motif, a genomic element 
which is enriched in promoter regions of genes related to embryo genome activation. The reprogramming 
efficiencies were however varying, and a gRNA function validation assay showed that the gRNAs used in 
this project were suboptimal for efficient gene activation in LCLs. The reprogramming method was 
nevertheless demonstrated to successfully convert five biobanked LCLs into bona fide iPSC lines. 
 
The iPSC lines generated in this thesis serve as a proof of concept that the novel CRISPRa reprogramming 
method works in biobanked LCLs and could be developed to systematically study the cell-type-specific 
reprogramming events in these cells. Also, the generated iPSC line collection constitutes the first iPSC 
collection derived from biobanked cells with the CRISPRa reprogramming method and is available as a 
future research resource, thus paving the way for the wider use of the LCL collections. 
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Tiivistelmä 
 
Biopankkeihin tallennetut lymfoblastoidisolulinjakokoelmat tarjoavat laajan biologisen datalähteen monien 
sairauksien tutkimiseen. Näitä verisoluista peräisin olevia solulinjoja on käytetty menestyksekkäästi 
tautisolumallina useissa in vitro -tutkimuksessa. Ne eivät kuitenkaan pysty täysin toistamaan 
sairausspesifisten primäärisolutyyppien kaikkia säätelyominaisuuksia, mikä on rajoittanut kokoelmien 
käytön vain tietynlaiseen tutkimukseen. Indusoituihin monikykyisiin kantasoluihin (iPS-soluihin) perustuva 
teknologia on kuitenkin tarjonnut uudenlaisen strategian kokoelmien monipuolisempaan hyödyntämiseen 
uusiutuvan lääketieteen, lääkekehityksen ja sairausmallinnuksen saralla. Lymfoblastoidisolujen 
solutyyppispesifisiä uudelleenohjelmointitapahtumia ei kuitenkaan tunneta tarkasti, mikä hidastaa uusien 
tehokkaampien ja luotettavimpien uudelleenohjelmointimenetelmien kehittämistä. CRISPR/Cas välitteinen 
geeniaktivaatio (CRISPRa) saattaa tarjota tähän uusia työkaluja, sillä se on jo valjastettu endogeenisten 
uudelleenohjelmointitapahtumien systemaattiseen tutkimiseen fibroblasteissa. 
 
Tämän Pro gradu -tutkielman tavoitteena oli osoittaa ensimmäistä kertaa CRISPRa välitteisen 
uudelleenohjelmointimenetelmän toimivuus THL Biopankin psykiatrisesta perhekokoelmasta saaduissa 
lymfoblastoidisolulinjoissa. Menetelmä perustuu solujen endogeenisten pluripotenssitekijöiden aktivointiin 
CRISPR-aktivaattoreilla, joka johtaa uudelleenohjemointiprosessiin soluissa. Eri 
pluripotenssitekijäkombinaatioiden joukosta löydettiin tehokkain yhdistelmä, ja tulosten perusteella näiden 
solulinjojen uudelleenohjelmointi näytti vaativan EEA-motiivin aktivoinnin. EEA-motiivi on genominen 
elementti, joka on rikastunut alkion genomiaktivaatioon liittyvien geenien promoottorialueille. 
Uudelleenohjelmointitehokkuus oli kuitenkin vaihteleva, ja osittaiseksi syyksi nähtiin projektissa 
käytettyjen opas-RNA:iden huono aktivaatioteho tässä solutyypissä. Menetelmä osoitettiin kuitenkin 
toimivaksi näissä soluissa, sillä viisi eri lymfoblastoidisolulinjaa saatiin onnistuneesti uudelleenohjelmoitua 
iPS-solulinjoiksi. 
 
Tässä projektissa tuotetut iPS-solulinjat ovat osoitus siitä, että CRISPRa välitteinen 
uudelleenohjelmointimenetelmä toimii biopankkeihin tallennetuissa lymfoblastoidisolulinjoissa, ja 
tulevaisuudessa menetelmää voidaan kehittää solutyyppispesifien uudelleenohjelmointitapahtumien 
systemaattiseen tutkimiseen. iPS-solulinjakokoelma on lisäksi ensimmäinen CRISPRa menetelmällä 
tuotettu kokoelma, joka on saatavilla tutkimukseen THL biopankista, näin mahdollistaen 
lymfoblastoidisolulinjakokoelmien laajemman tutkimuskäytön. 
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Abbreviations 
 
AP  alkaline phosphatase 
Cas  CRISPR associated protein 
cDNA  complementary DNA 
CRISPR  clustered regularly interspaced short palindromic repeats 
CRISPRa  CRISPR mediated gene activation 
DSB  double stranded break 
E8  Essential 8 medium 
EB  embryoid body 
EBNA-1  EBV nuclear antigen 1 
EBV  Epstein-Barr virus 
EEA  EGA enriched Alu element motif 
EGA  embryonic genome activation 
ESC  embryonic stem cell 
FACS  fluorescence activated cell sorting 
GFP  green fluorescent protein 
gRNA  guide-RNA 
HFF  human foreskin fibroblast 
H3K27ac  histone H3 lysine 27 acetylation marker 
H3K27me3  histone H3 lysine 27 trimethylation marker 
ICC  immunocytochemistry 
ID PCR  identification genotyping with polymerase chain reaction 
iPSC  induced pluripotent stem cell 
KLF4  Krüppel-like factor 4 
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LCL  lymphoblastoid cell line 
MET  mesenchymal-to-epithelial transition 
MG  matrigel 
miRNA  micro-RNA 
mRNA  messenger RNA 
NaB  sodium butyrate 
OCT4  octamer binding protein 4 
OriP  origin of plasmid replication 
OSKM  OCT4, SOX2, KLF4, C-MYC 
PAM  protospacer adjacent motif 
PCR  polymerase chain reaction 
PDL  population doubling level 
PP  pluripotency 
PSC  pluripotent stem cell 
RE  regulatory element 
ROCK  Rho-associated protein kinase 
RT  room temperature 
RTase  reverse transcriptase 
RT-qPCR  reverse transcription quantitative polymerase chain reaction 
SAM  synergistic activation mediator 
SEM  standard error of the mean 
shp53  silencing hairpin RNA for p53 
SOX2  Sry (sex determining region y)-box 2 
TF  transcription factor 
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THL  National Institute for Health and Welfare (in Finnish Terveyden ja 
hyvinvoinnin laitos) 
VPR  VP64-p65-Rta activation system 
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1. Introduction 
 
1.1. Lymphoblastoid cell lines 
 
1.1.1. Epstein-Barr virus mediated transformation of B cells 
 
Epstein-Barr virus (EBV) is a herpes virus, which usually causes an asymptotic infection, where it 
latently infects B cells, but it can also cause infectious mononucleosis, and the virus has been 
causally associated to multiple lymphomas and carcinomas, such as Burkitt’s lymphoma and 
Hodgkin’s disease (reviewed in Niedobitek et al. 2001). In vitro EBV infection of peripheral blood G0 
phase B cells transforms the cells into actively proliferating lymphoblastoid cell lines (LCLs) 
(Sugimoto et al. 2004). The EBV genome resides in the infected cells as a high copy episome, which 
expresses a small subset of its genes (Babcock et al. 2000). The most upstream gene, which governs 
all the necessary functions of the EBV genome is the EBV nuclear antigen 1 (EBNA-1). It regulates 
the episome replication through interactions with the origin of plasmid replication (OriP) (Yates et 
al. 1985) and controls the faithful partitioning of the episome copies to daughter cells during mitosis 
by interacting with the segregating chromosomes (Wu et al. 2000). EBNA-1 is also the most 
upstream gene regulating the transformation process, as it activates the EBV transforming genes 
(Altmann et al. 2006), which subsequently activate the expression of several host cell genes related 
to cell cycle control and proliferation, such as cyclin D2, cyclin dependent kinase 4 and proto-
oncogene C-MYC (Kaiser et al. 1999; Spender et al. 2001), resulting in the induction of proliferation. 
 The EBV-transformed LCLs can sometimes undergo immortalization, and the cell lines 
can be divided into two groups based on their immortalization status: the pre-immortal and the 
post-immortal LCLs. Pre-immortal LCLs are characterized by having a high proliferation rate, normal 
karyotype, and a low or non-existing telomerase activity (Sugimoto et al. 2004). These LCLs can be 
maintained up to 160 population doubling levels, after which they go into a proliferation crisis due 
to the shortening of telomeres, and the cell population dies (Sugimoto et al. 2004; Sugimoto et al. 
1999). Post-immortal LCLs are also highly proliferative but, in contrast to pre-immortal LCLs, they 
are characterized by aneuploidy or other chromosomal aberrations as well as high telomerase 
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activity (Sugimoto et al. 2004), and they can be tumorigenic (Takahashi et al. 2003). Because of the 
high telomerase activity, the post-immortal cells do not undergo the proliferation crisis and can be 
maintained in culture seemingly infinitively (Sugimoto et al. 2004). 
 
1.1.2. Research with biobanked LCLs 
 
Biobanks and cell repositories have been using the establishment of LCLs as a convenient method 
to ensure a perpetual source of patient specific DNA and other biomolecules for over two decades. 
There are vast collections of LCLs from patients with various diseases, including rare genetic 
disorders, which offer a rich bioresource for disease research. For example, the NIMH Repository 
and Genomics Resource alone stores over 96,000 LCLs from patients with different mental disorders 
and control groups and almost the same number of DNA samples derived from LCLs, available for 
researchers (NIMH 2018). Some collections also include samples from non-affected family members 
or already established comprehensive genotypic or phenotypic datasets (Auton et al. 2015), further 
increasing their research value.  
Biobanked LCLs have been widely used as a surrogate in vitro cell model when the 
primary tissue is not readily available. This is the case with disorders affecting the central nervous 
system, and LCLs have been used in a wide array of neurological and psychiatric disorder studies. 
These studies have unveiled for example new risk loci for schizophrenia (Ripke et al. 2011), 
depression (Holmans et al. 2007) and bipolar disorder (Sklar et al. 2011), as well as disease specific 
gene regulation patterns in autism (Hu et al. 2006). LCLs have also been used to study the host 
response to gene knockdowns (Mei et al. 2006; Badhai et al. 2009), drugs (Watters et al. 2004; Duan 
et al. 2007) and other cell perturbations (Correa & Cheung 2004; Niu et al. 2010). 
 Even though LCLs have been a conducive surrogate cell model in numerous studies, 
their ability to faithfully recapitulate the regulatory prospects of the primary tissue cells has been 
negated in several studies. The EBV transformation may cause differential expression levels of a 
subset of genes (Carter et al. 2002; Min et al. 2010; Çalişkan et al. 2011) or alter the DNA methylation 
patterns (Çalişkan et al. 2011; Hannula et al. 2001). LCLs have been shown to exhibit cell type specific 
alternative splicing (Monnier et al. 2003), and the chromosomal aberrations in post-immortal LCLs 
may affect research results (Redon et al. 2006; Okubo et al. 2001; Sugimoto et al. 2004). As a 
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consequence, the extensive LCL collections can be used only for certain type of studies, precluding 
their thorough utilization. 
 Recently, the emergence of iPSC technology has offered new perspectives for the use 
of the biobanked LCL collections. With the technology, the vast collections could be utilized more 
comprehensively in wider research applications. 
 
1.2. Pluripotency reprogramming and induced pluripotent stem cell technology 
 
1.2.1. Induced pluripotent stem cells 
 
As cells differentiate from a pluripotent into a somatic state, they become gradually fixed on just 
one cell fate. Once fully matured, the cells have obtained a cell type specific epigenetic state, which 
governs how genes are regulated, thus dictating their phenotype. The epigenetic state of the 
differentiated cells is “locked” by DNA methylation patterns, which ensures that the cells stay in 
that particular state and cannot spontaneously revert back to pluripotency or to any other cell fate. 
However, somatic cells can be reprogrammed in vitro into a pluripotent state resembling that of an 
embryonic stem cell (ESC) with the ectopic overexpression of a small set of pluripotency-associated 
transcription factors (TFs) known as reprogramming factors. The most well-known factors are the 
so-called “Yamanaka factors”: OCT4, SOX2, KLF4 and C-MYC (OSKM) (Takahashi & Yamanaka 2006; 
Takahashi et al. 2007). The reprogrammed cells are known as induced pluripotent stem cells (iPSCs). 
iPSCs are indistinguishable from ESCs, as they are pluripotent, have an unlimited self-renewal 
capacity and the potential to differentiate into all three germ layers, and they can contribute to the 
germline cells. Other pluripotent stem cell (PSC) characteristics are the high alkaline phosphatase 
level, which is often used for initial iPSC characterization; high nucleus-to-cytosol ratio and tightly 
packed colonies in cell culture; as well as the expression of pluripotency related markers, such as 
OCT4, SOX2, TRA-1-60 and TDGF1 (Martí et al. 2013). 
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1.2.2. Reprogramming to pluripotency 
 
To reprogram somatic cells, reprogramming factors are introduced to the cells as transgenes, 
mRNAs or proteins (Hu 2014). One of the most used methods is the introduction of the factors as 
transgenes with non-integrative OriP/ EBNA-1 episomal plasmids (Okita et al. 2011). The ectopic 
overexpression of the reprogramming factors in cells results in the factors binding to any available 
target sites in the host genome (Chronis et al. 2017). This binding causes an array of stochastic 
events, which leads to a multistep process that can eventually result in the conversion of somatic 
cells into iPSCs. The complicated process is not well understood, but recent studies have provided 
some insights into the whole phenomenon (reviewed in for example Wang et al. 2017; Buganim et 
al. 2013). 
 The key event in reprogramming is the reconfiguration of the epigenome from the 
somatic into the pluripotent state. During the somatic state, the cell-type-specific genes are active, 
while the pluripotency-associated genes are silenced with such silencing histone markers as the 
histone H3 lysine 27 trimethylation (H3K27me3) (Wang et al. 2017). During the pluripotent state, 
on the other hand, the pluripotency-associated genes are active, and marked with histone markers 
such as histone H3 lysine 27 acetylation (H3K27ac) (Wang et al. 2017). The pluripotent state has also 
a characteristic poised state, where the different developmental pathways are suppressed but kept 
in a state, in which they are ready to respond to any differentiation cues (Wang et al. 2017). The 
reprogramming process can be divided into a stochastic and a hierarchal phase (Buganim et al. 
2012). During the initial stochastic phase, the ectopic expression of reprogramming factors causes 
stochastic gene activation as they bind to their target sites. The binding causes the first major wave 
of transcriptomic (Polo et al. 2012), proteomic (Hansson et al. 2012) and epigenomic (Knaupp et al. 
2017) reconfiguration, during which the cells start to lose their identity, undergo metabolic changes 
and gain higher proliferation rate (Polo et al. 2012; Hansson et al. 2012; Smith et al. 2010). The 
reprogramming factors can recruit chromatin remodeling complexes to their binding sites, and 
induce changes to the chromatin accessibility (Koche et al. 2011; Knaupp et al. 2017). Chromatin 
remodeling during the initial phase includes the silencing of the somatic gene regulatory elements 
(REs), that is the enhancers and promoters, and the activation of the early pluripotency gene REs 
(Knaupp et al. 2017). There is also a group of REs, which are transiently opened during the 
reprogramming process, but closed before the process is completed, possibly facilitating in the 
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chromatin accessibility during the process (Knaupp et al. 2017). The closing of active loci requires 
the replacement of the activating histone markers, such as the H3K27ac, with repressing ones, like 
H3K27me3, while during the activation of silenced loci, the markers are replaced vice versa. 
Throughout the early and intermediate phases of reprogramming, the cells gradually lose their cell-
type-of-origin-specific DNA methylation patterns, mostly through passive, replication-dependent 
demethylation (Knaupp et al. 2017). 
It has been suggested, that after the first wave the cells must undergo the stochastic 
activation of at least one of the genes, that belong to the subset of early pluripotency genes, i.e. 
Esrrb, Utf1, Lin28 and Dppa2, which can initiate the activation of the rest of the pluripotency 
network (Buganim et al. 2013). The activation of these early pluripotency genes is thought to be the 
rate-limiting step during the reprogramming process, as most of the cell population goes through 
the initial stochastic events but only a fraction of the cells can give rise to iPSCs. Once the rate-
limiting step is passed, the early pluripotency genes activate SOX2, which is considered to mark the 
onset of the late hierarchical phase (Buganim et al. 2012). The endogenous SOX2 governs the 
activation of the rest of the pluripotency network, and the second major wave of reconfiguration 
occurs in the cells (Buganim et al. 2012). The somatic loci are silenced, and the late pluripotency-
associated loci are activated as they become more accessible for the chromatin remodeling 
complexes, thus constituting an ESC-like epigenomic state (Knaupp et al. 2017). During the late 
phase, the DNA methylation starts to occur more rapidly and seems to rely on the higher expression 
of the endogenous demethylases TET1 and TET2 (Knaupp et al. 2017). The genome also acquires 
new methylation patterns, and it seems that once the ESC-like epigenome has been established, the 
new DNA methylation patterns “lock” the state (Knaupp et al. 2017). Once the pluripotent state has 
been acquired, the ectopic reprogramming factor genes are silenced, and the pluripotent state is 
stabilized (Golipour et al. 2012). 
 
1.2.2.1. Reprogramming of different cell types 
 
Most of the studies about the reprogramming process have been conducted with human or murine 
fibroblasts. It was recently demonstrated that depending on the cell type of origin the cells undergo 
cell-type-specific transcriptomic changes and the reprogramming process follows a cell-type-
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specific trajectory (Nefzger et al. 2017). Since different cell types express different sets of genes, 
which make up their phenotype, the loss of identity occurs in a cell-type-specific manner, as the cell 
identity related genes are downregulated (Nefzger et al. 2017). The re-activation of the pluripotency 
network occurs also partially in a cell-type-specific manner, and it was discovered that for example 
the mesenchymal-to-epithelial transition (MET), which has been considered crucial for 
reprogramming based on studies in fibroblasts, does not occur in keratinocytes (Nefzger et al. 2017). 
The transcriptome analysis nevertheless revealed some universal events that took place in all 
studied cell types. All cell types exhibited two major waves of transcriptomic resetting in the 
beginning and end of the reprogramming process, though the genes that were differentially 
expressed during the waves in each cell type varied (Nefzger et al. 2017). There were also some 
somatic genes, which were universally downregulated during the loss of identity, such as Egr1, 
which has been shown to impede reprogramming (Nefzger et al. 2017). The bona fide iPSCs 
generated from different cell types of origin were indistinguishable based on transcriptome studies 
(Nefzger et al. 2017), though other studies have shown that early passage iPSCs differ from each 
other based on their cell type of origin in their epigenetic memory, but the differences are abolished 
with further passaging (Polo et al. 2010). 
 
1.2.3. Reprogramming factors 
 
Reprogramming has been widely conducted and studied by using the four Yamanaka factors, but 
additional factors have been discovered to improve the reprogramming efficiency or to substitute 
some or all of the canonical factors (reviewed in Xiao et al. 2016; Theunissen & Jaenisch 2014). The 
reprogramming factors are usually pluripotency-associated TFs, that exhibit master TF as well as 
pioneer factor properties. As a master TF, the reprogramming factors are capable of controlling the 
expression of a set of genes required for a specific cell identity program, in this case the pluripotency 
program. Pioneer factors, on the other hand, are capable of recognizing their target loci in closed 
chromatin regions and making the loci more accessible for other TFs to bind. This is necessary, since 
during the somatic cell program, the pluripotency related loci reside in closed chromatin. In this 
thesis work, the effects of eight reprogramming factors were studied: OCT4, SOX2, KLF4, C-MYC, L-
MYC, LIN28, NANOG and REX1. 
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OCT4 
OCT4 (octamer-binding transcription factor 4, also known as POU5F1) was the first master regulator 
of the pluripotent state to be discovered (Nichols et al. 1998). It is one of the core pluripotency 
factors together with SOX2 and NANOG, and it regulates several pluripotency-associated functions 
in the cell, such as proliferation, stem cell maintenance and cell metabolism (Kim et al. 2008; Xiao 
et al. 2016). OCT4 could be considered the most important pluripotency factor and it can be 
replaced in the reprogramming factor combinations only with factors that are able to activate the 
endogenous OCT4 (Radzisheuskaya & Silva 2014; Xiao et al. 2016). During reprogramming, OCT4 
forms a heterodimer with SOX2, and the dimer functions as a pioneer TF, which is capable of 
activating pluripotency genes (Tapia et al. 2015). OCT4 has an important role in chromatin 
remodeling as it has been shown to interact with several chromatin remodeling complexes (van den 
Berg et al. 2010).  OCT4 has also been suggested to facilitate MET (Radzisheuskaya & Silva 2014). 
 
SOX2 
SOX2 (sex determining region of the Y-box 2) is one of the core regulators of the endogenous 
pluripotency network (Kim et al. 2008). In ESCs, SOX2 has an important function in maintaining self-
renewal and pluripotency (Xiao et al. 2016). The endogenous SOX2 plays an important role during 
the reprogramming process as its activation has been hypothesized to mark the onset of the 
hierarchal phase (Buganim et al. 2012). During reprogramming the ectopic SOX2 functions as a 
OCT4-SOX2 heterodimer TF (Tapia et al. 2015). 
 
KLF4 
KLF4 (Krüppel-like factor 4) is related to regulation of proliferation, apoptosis, tissue homeostasis, 
embryo development and cytodifferentiation (Xiao et al. 2016). It is irreplaceable in naïve human 
iPSC state, where it controls the naïve pluripotency circuitry (Liu et al. 2017). During reprogramming, 
it is crucial to express the factor at a high enough level for the process to be completed correctly, 
and arrested reprogramming can be saved in some cases with upregulation of KLF4 (Nishimura et 
al. 2014). KLF4 seems to have a dual function during the reprogramming process, since during the 
early phase it has been shown to repress genes related to differentiation (Polo et al. 2012) and 
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during the late phase it activates pluripotency genes by promoting transcriptional pause release (Liu 
et al. 2014). 
 
C-MYC and L-MYC 
C-MYC and L-MYC are members of the MYC family of TFs. C-MYC functions as general amplifier of 
transcription by inducing the RNA polymerase II pause release (Nie et al. 2012; Rahl et al. 2010). It 
is involved in several important functions in PSCs, such as cell growth and proliferation, metabolism, 
differentiation, apoptosis, senescence, stem cell renewal, embryonic development and cell 
adhesion (Xiao et al. 2016). During reprogramming it amplifies the expression of all active genes, 
both pluripotent and somatic ones (Nie et al. 2012). Reprogramming is possible without C-MYC, but 
it greatly enhances the efficiency (Nakagawa et al. 2008). In iPSCs, the transcriptional network 
governed by C-MYC has been shown to be separate from the core pluripotency network (Kim et al. 
2008). However, C-MYC is also a known oncogene, but it can be readily replaced with L-MYC, which 
improves the reprogramming efficiency of human fibroblasts more than C-MYC does (Nakagawa et 
al. 2008). L-MYC is similar to C-MYC in function, except it lacks the domain which contributes to the 
oncogenic properties, making it a safer choice for iPSC generation (Okita & Yamanaka 2011).  
 
NANOG 
NANOG is the third main factor in the core pluripotency network, together with OCT4 and SOX2 
(Kim et al. 2008), and required for the formation and maintenance of pluripotency in ESCs (Mitsui 
et al. 2003). Nanog is a very specific marker of pluripotent cells and has been shown to contribute 
to the ground pluripotency state (Silva et al. 2009). However, NANOG is not required for the 
induction of pluripotency, but it improves the reprogramming efficiency or can be used to replace 
other factors (Schwarz et al. 2014; Xiao et al. 2016). 
 
LIN28 
LIN28 (also known as LIN28A) has been considered to be a robust marker during the intermediate 
phase of reprogramming, marking the cells that will undergo the full reprogramming process 
(Buganim et al. 2013). It has been suggested that LIN28 is one of the genes that can either directly 
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or through other factors activate the endogenous SOX2 (Buganim et al. 2012). In PSCs, LIN28 inhibits 
differentiation by repressing Let-7 microRNAs (Viswanathan & Daley 2010). During reprogramming, 
it also recruits the TET1 chromatin remodellers to closed genomic sites to make them more 
accessible (Zeng et al. 2016). 
 
REX1 
REX1 (also known as ZFP42) is expressed in undifferentiated cells (Chen & Gudas 1996). It is directly 
regulated by OCT4 and indirectly regulated by SOX2 and NANOG, making it an important part of the 
pluripotency network (Ben-Shushan et al. 1998; Shi et al. 2006). It has a role in development, 
maintaining the undifferentiated state as well as cell cycle regulation (Scotland et al. 2008). REX1 
has also been shown to improve reprogramming by impeding such reprogramming barriers as 
growth arrest and apoptosis (Son et al. 2013). 
 
Other factors 
On top of the transcription factors used to reprogram cells, there are several other factors, which 
are used to improve reprogramming or to replace reprogramming factors. These factors can be 
small molecules or micro-RNAs (miRNAs) (reviewed in Xiao et al. 2016). Also, endogenous factors or 
signaling pathways, which impede the reprogramming process, can be repressed with interference 
methods to improve reprogramming. In this thesis work, sodium butyrate (NaB) and short hairpin 
RNA against p53 (shp53) were used. NaB improves the reprogramming process by upregulating the 
expression of pluripotency-related miR302/367 cluster and increasing the stability of the miRNAs 
(Zhang & Wu 2013). This miRNA cluster has been shown to promote MET and thus enhance 
reprogramming (Liao et al. 2011). Reprogramming has been shown to induce a cellular stress 
response, which causes the upregulation of p53, which in turn can induce either apoptosis or cell 
cycle arrest and therefore interfere with the reprogramming process (Marión et al. 2009). 
Expression of shp53 causes the repression of p53, decreases the stress response and improves the 
reprogramming efficiency (Hong et al. 2009). 
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1.2.4. Prospects of iPSC technology 
 
iPSC technology holds great promise for the development of disease models, drug discovery and 
regenerative medicine, and it has resolved several ethical issues surrounding the use of ESCs in 
similar research (Shi et al. 2017). In disease modeling, virtually any cell type from a patient can be 
converted into iPSCs, which are then differentiated into the cell type or tissue affected by the 
disease and the effects of the disease can be studied in vitro. Monogenic diseases have been widely 
studied since the disease-causing mutation can be corrected with a gene editing platform, such as 
the CRISPR/Cas9, which results in an isogenic control. Similarly, a mutation can be introduced into 
a healthy iPSC line to study its effects. With an isogenic control, the only differences between the 
healthy and disease cells are the ones caused by the disease mutation. The iPSC technology enables 
also the study of disease-specific cells which would be unattainable otherwise, such as neurons, and 
for example several iPSC-derived neuronal models have been generated for Alzheimer’s disease 
alone (reviewed in Shi et al. 2017). iPSC-derived somatic cells offer also a new strategy for drug 
discovery and research (Shi et al. 2017). Drug testing has been heavily dependent on animal models, 
but there are inadequacies regarding the capability of animals to recapitulate all the effects of the 
diseases or tested drugs that occur in humans (Puzzo et al. 2015). With iPSC technology, the effects 
of drugs on their target cell types, such as neurons, can be studied in vitro, which can reduce the 
amount of expensive, failed late-stage clinical trials in the future (Shi et al. 2017). Wide drug screens 
have also been conducted to study the effects of already existing drugs on other cell types 
(Yamashita et al. 2014). In iPSC technology derived regenerative medicine, patient derived iPSCs are 
generated, possible mutations corrected, and the cells are then differentiated into the desired cell 
type. These somatic cells are used to replace damaged or non-functioning tissue. iPSCs offer the 
possibility to generate autologous, non-immunogenic somatic cells for patients, thus mitigating the 
potential health and safety issues, which could rise from allologous ESC-derived cells (Shi et al. 
2017). Clinical trials using iPSCs in regenerative medicine have been focused mostly on eye diseases 
and neural repair (reviewed in Takahashi 2018). 
 iPSC technology also offers new possibilities for wider utilization of the LCL collections 
since the cells could be reprogrammed and differentiated into the desired cell type to study the 
disease specific cell types in vitro. By utilizing the already existing collections, researchers would not 
have to collect new samples from patients, thus saving time and resources. LCLs have been 
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reprogrammed previously into bona fide iPSCs (Kumar et al. 2016; Choi et al. 2011; Rajesh et al. 
2011; Barrett et al. 2014; Thomas et al. 2015; Banovich et al. 2018; Son et al. 2017). Given that most 
of the reprogramming methods have been developed for fibroblasts, LCLs have been proven to need 
optimization of the conventional methods in order to be efficiently reprogrammed (Kumar et al. 
2016). iPSC technology derived research has been modest with LCLs, but LCL-derived iPSCs have 
been used to model Parkinson’s disease (Fujimori et al. 2016). In the study, iPSCs derived from the 
LCL and fibroblasts of a Parkinson’s disease patient were generated and differentiated into neural 
cells. The iPSCs from both cell types were found to have the same differentiation potential, and no 
differences were found between the derived neural cells. These results demonstrated that LCLs hold 
great potential for disease modeling and other iPSC technology related research. 
 In order to fully utilize the potential of the LCL collections, more efficient 
reprogramming methods should be developed which would result in higher quality iPSCs. To achieve 
this, the endogenous events, that are crucial for successful reprogramming of LCLs, have to be 
understood. However, the conventional reprogramming methods rely mostly on the overexpression 
of ectopic reprogramming factors, which instigate an array of stochastic events. The abundance of 
these events masks the reprogramming-wise necessary ones. This makes it impossible to identify 
the key factors or epigenomic changes, that should be targeted during reprogramming to achieve 
more efficient process and higher quality iPSCs. In order to systematically study the endogenous 
reprogramming events, the CRISPR/Cas genome editing platform has been harnessed for 
reprogramming in fibroblasts but is yet to be established in LCLs. 
 
1.3. CRISPRa mediated reprogramming 
 
1.3.1. CRISPR/Cas 
 
Clustered regularly interspaced palindromic repeats (CRISPR)/CRISPR-associated (Cas) system has 
been adapted for gene editing purposes from the acquired immunity of prokaryotes (Jinek et al. 
2012; Mali, Yang, et al. 2013). The technology has enabled a fast, easy and inexpensive way to create 
specific gene mutations. It is composed of only two components: the Cas9 protein and a guide-RNA 
(gRNA), which are easily engineered and expressed in cells to achieve the desired mutation (Jinek 
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et al. 2012). Cas9 is an endonuclease which has two nuclease domains, making it capable of eliciting 
double stranded breaks (DSBs) to DNA (Garneau et al. 2010). The gRNA is a short RNA fragment, 
which has a Cas9 binding region and a spacer region (Jinek et al. 2012). Once both components are 
expressed in cells, the gRNA binds to Cas9 and the complex is then guided to its target site in the 
host genome, based on the ~20 nucleotides long spacer sequence, which is complementary to that 
in the target site. The target site in the host genome is called a protospacer, and it has to contain a 
protospacer adjacent motif (PAM) after its 3’ end, for the Cas9 to be able to bind to it. Different 
prokaryotic species have different PAM sequences for their Cas9 proteins (Mojica et al. 2009). The 
most widely used Cas9 is from Streptococcus pyogenes, the PAM sequence of which is NGG, N being 
any nucleotide (Mojica et al. 2009). Once the Cas9-gRNA complex has bound to its target site, the 
Cas9 undergoes a conformational change so that it is able to elicit a DSB near the target site (Jinek 
et al. 2014). The DSB is repaired by the repair machinery of the cell, either via non-homologous end 
joining, which usually results in knock-out mutants, or homology directed repair, via which it is 
possible to introduce new genetic material into the cells (Mali, Yang, et al. 2013). 
 
1.3.2. CRISPR/Cas9 mediated gene activation 
 
By introducing point mutations to the two active sites of the Cas9 endonuclease, it is possible to 
render the protein catalytically inactive without interfering with its DNA binding properties. This 
deactivated, “dead” Cas9 (dCas9), is a protein which is capable of binding to essentially any genomic 
site with a PAM sequence next to it, guided by a short gRNA, and several applications of the platform 
have been developed by engineering either one or both of the components. These applications 
enable for example labeling of sequence specific loci in the genome (Knight et al. 2018), remodeling 
of chromatin (Pulecio et al. 2017) and multiplexed regulation of gene circuitries (Jusiak et al. 2016). 
In this thesis the CRISPR/dCas9 platform was used for gene activation. 
 In CRISPR mediated gene activation (CRISPRa), a transcriptional activator domain is 
fused to the dCas9 and the protein complex can be used as an artificial TF when directed to the 
promoter region of a target gene (Perez-Pinera et al. 2013; Maeder et al. 2013). The dCas9 complex 
can functionally open chromatin when targeted to closed chromatin regions, thus exhibiting pioneer 
factor properties (Barkal et al. 2016). Various transcriptional activator domains, which have 
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different mechanisms of function, have been used for CRISPRa (table 1). Some activator domains 
recruit the transcriptional machinery to the target site (e.g. VP64), while others activate gene 
expression by marking the histones with activating H3K27ac markers (p300). More advanced 
activator systems constitute of several domains synergistically improving the gene activation, and 
for example the SunTag system can recruit multiple activator domains to a single dCas9 protein 
(Tanenbaum et al. 2014). 
 
 
 
Because the gRNAs are short and easily expressed in cells, it is possible to 
simultaneously target and regulate several genes or complete gene networks in cells (Cheng et al. 
2013; Dominguez et al. 2015). This high multiplexing capability of the CRISPR/dCas9 platform and 
the pioneer TF properties of the dCas9 offer the possibility to activate the endogenous pluripotency 
network genes and induce reprogramming without any ectopic reprogramming factors. 
 
Table 1.  Different activator domains and systems used for CRISPRa
Activator 
domain/ 
system
Components Targeted 
locus
Mechanism of function References
VP64 4 tandem repeats of the viral 
VP16 transcriptional activator
Promoters Recruitment of 
transcriptional activators
(Perez-Pinera et al. 2013; 
Maeder et al. 2013)
VP160 10 repeats of VP16 Promoters Recruitment of 
transcriptional activators
(Cheng et al. 2013)
VP192 12 repeats of VP64 Promoters Recruitment of 
transcriptional activators
(Balboa et al. 2015)
p65 The NF-kB trans-activating 
subunit
Promoters Recruitment of 
transcriptional activators 
and chromatin remodellers
(Gilbert et al. 2013; 
Konermann et al. 2015)
p300 core The catalytic core of 
acetyltransferase
Promoters 
and 
enhancers
Histone acetyltransferase (Hilton et al. 2015)
VPR VP64-p65-Rta Promoters Recruitment of 
transcriptional activators
(Chavez et al. 2015)
SunTag Multiple effector domains (such 
as VP64 or p65) recruited to 
single peptide fused to dCas9
Depends 
on effector 
domains
Depends on effector 
domains
(Tanenbaum et al. 2014; 
Gilbert et al. 2014)
SAM VP64 fused to dCas9, gRNA 
with binding sites for two MS2 
aptamers, MS2-p65-HSF1
Promoters Recruitment of 
transcriptional activators
(Konermann et al. 2015)
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1.3.3. CRISPRa mediated reprogramming 
 
CRISPRa mediated reprogramming has already been demonstrated in mouse and human fibroblasts. 
The mouse work focused on studying the necessary endogenous events required for 
reprogramming (Liu et al. 2018). In their work, Ding and colleagues first showed that iPSCs can be 
generated by targeting several factors of the pluripotency network with a dCas9-SunTag-VP64 
system (Liu et al. 2018). They also demonstrated that by using a dCas9-SunTag-p300core system, 
the targeting and epigenetic remodeling of the promoter region of Sox2 or the promoter and 
enhancer regions of Oct4 are enough to induce successful reprogramming of mouse fibroblasts (Liu 
et al. 2018).  The work demonstrated the importance of epigenetic remodeling during 
reprogramming, and also that the effects of individual events on reprogramming can be studied 
systematically with CRISPRa without the masking effects of the ectopic factors (Liu et al. 2018). 
In the human fibroblast reprogramming, Otonkoski and colleagues (Weltner et al. 
2018) showed that the CRISPRa system enables the utilization of genomic elements to improve the 
reprogramming process, which is impossible with transgenic methods. They targeted the promoter 
regions of several pluripotency network genes as well as the recently discovered EEA motifs with a 
dCas9-VP192 activator complex (Weltner et al. 2018). The EEA motif, or embryonic genome 
activation (EGA) enriched Alu element motif, is a 36-base-pair-long genomic element that is 
enriched in the promoter regions of genes related to EGA (Töhönen et al. 2015). The EEA motif is 
abundant in the human genome and it has been suggested to have a role during EGA (Töhönen et 
al. 2015). In CRISPRa mediated reprogramming, the targeting of the EEA motif was shown to 
improve the reprogramming efficiency by an order of magnitude (Weltner et al. 2018). The targeting 
of the EEA motif enhanced the expression of a subset of pluripotency genes, including NANOG and 
REX1 (Weltner et al. 2018). According to the suggested mechanistic model, the dCas9 complex 
binding to the EEA motifs in the promoters of pluripotency-associated genes renders the chromatin 
more accessible near the binding sites, thus facilitating the activation of the genes (Weltner et al. 
2018). 
The novel CRISPRa mediated reprogramming method could enable us to 
systematically determine the necessary endogenous events required for efficient reprogramming 
of LCLs and to utilize the genomic elements in the process. With the method, the speculated rate-
limiting steps, such as the stochastic activation of Esrrb, Utf1, Lin28 or Dppa2, could be directly 
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targeted and their effects could be studied. This will help in the development of more efficient and 
cell-type-specific reprogramming methods. By specifically targeting the crucial factors and events 
during reprogramming, the resulting iPSCs could also prove to be of higher and more standardized 
quality, which subsequently results in higher-quality downstream applications. 
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2. Aim of the thesis 
 
The emergence of iPSC technology has offered new possibilities for the more thorough utilization 
of the vast lymphoblastoid cell line collections in biobanks worldwide. In order to develop more 
efficient reprogramming methods, which will give rise to higher-quality iPSCs, it is important to 
understand the cell-type-specific endogenous events taking place during the reprogramming 
process. The novel CRISPRa mediated reprogramming method enables the systematic study of the 
endogenous reprogramming events without the masking effects of the ectopic factors and 
stochasticity in transgenic reprogramming methods. The CRISPRa method also enables the 
utilization of genomic elements, which is not plausible with conventional methods. 
This thesis work aimed to establish the novel CRISPRa mediated reprogramming 
method, described by Otonkoski and colleagues (Weltner et al. 2018), for the first time in biobanked 
LCLs. The aim was to derive bona fide iPSC lines from the LCLs, obtained from the Psychiatric Family 
Collections of the THL Biobank, characterize the generated lines and return them back to the 
biobank as a future research resource. The generated collection would serve as the first ever iPSC 
line collection derived from biobanked cells with the CRISPRa method and would pave the way for 
the wider use of the collected LCLs. 
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3. Materials and methods 
 
3.1. Lymphoblastoid cell lines 
 
The lymphoblastoid cell lines used in this project were obtained from THL Biobank by an application 
process. LCLs were selected from the Psychiatric Family Collections of THL Biobank and selection 
was made in collaboration with the original researchers based on the future research potential of 
produced iPSCs in biobank. The lines were labeled as IB-D1 through IB-D6 in this project. 
Experimental work with the cell lines was carried out under the contract and general terms of THL 
Biobank (permission no BB2016_56). 
 
3.2. Plasmids 
 
The activator plasmid was pCXLE-dCas9VP192-GFP-shp53 (Addgene #69535) and gRNAs were 
cloned to GG-dest plasmid (Addgene #69538). The gRNAs used in this thesis were OCT4.1, OCT4.4, 
OCT4.5, SOX2.4, SOX2.3, KLF4.2, KLF4.3, CMYC.3, CMYC.5, EEA.1, EEA.2, EEA.3, EEA.7, EEA.10, 
NANOG.3, NANOG.4, NANOG.1, NANOG.2, NANOG.5, LIN28.1, LIN28.2, LIN28.3, LIN28.4, LIN28.5 
REX1.10 and REX1.8 as described in (Weltner et al. 2018). Transgenic reprogramming plasmids were 
pCXLE-hOCT3/4-shp53-F (Addgene #27077), pCXLE-hSK (Addgene #27078), and pCXLE-hUL 
(Addgene #27080). Control GFP plasmid was pCXLE-EGFP (Addgene #27082). 
Plasmids were prepared from glycerol stocks with NucleoBond® Xtra Midi Plus EF kit 
(Macherey-Nagel, 740422) according to the user manual, yielding a final concentration of 0.5 – 2 
μg/μl, measured with SimpliNanoTM Spectrophotometer (Biochrom). 
 
3.3. Cell culture 
 
Lymphoblastoid cells were cultured in lymphoblastoid cell medium (RPMI 1640 with GlutaMAXTM 
(Life Technologies, 61870-010), 15 % fetal bovine serum (FBS; Life Technologies, 10270-106), 1 μM 
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Sodium Puryvate (Lonza, BE13-115E)) in suspension, in cell culture flasks which were kept upright. 
Cell density was kept between 0.5 – 1.5 * 106 cells/ml. Culture was passaged as follows: cells were 
transferred to a conical tube, centrifuged 200 g, 5 min, at room temperature (RT) (Eppendorf, 
Centrifuge 5810 R), and the cell pellet was re-suspended to new medium. When transferring cells 
to conical tube and re-suspending the cell pellet, the culture was pipetted multiple times to ensure 
single cell suspension. Cells were counted from a single cell suspension sample taken from 
transferred culture with Countess® Automated Cell Counter (Life Technologies) according to the 
user manual. New medium was added when needed between passaging without disrupting cell 
clusters. 
 Human foreskin fibroblasts (HFFs; ATCC line CRL-2429) were cultured in fibroblast 
medium (DMEM (Sigma, D6546), 10 % FBS (Life Technologies, 10270-106), 1 % GlutaMAXTM (Life 
Technologies, 35050-038)). Culture was passaged once the confluence was above 80 % as follows: 
cells were washed twice with phosphate buffered saline (PBS; Sigma, D8537), detached with 
TrypLETM (Life Technologies, 12563-029) by incubating at +37 °C, 3 min, fibroblast medium was 
added and the culture was centrifuged 5 min, 200 g, RT. The cell pellet was re-suspended to 
fibroblast medium, cells were counted with Countess®, and plated with desired dilution. 
iPSCs were cultured on Matrigel (MG; Corning, 356231) coated plates in Essential 8 
(E8) medium (Life Technologies, A1517001) or in E8 Flex (Life Technologies, A2858501). E8 was 
changed every day, and E8 Flex enabled medium change intervals of up to 72 hours. iPSCs were 
passaged when colonies had grown to optimal size to remain viable after passaging. Passaging was 
done as follows: medium was aspirated, 0.5 mM EDTA (Life Technologies, 15575020) was added 
and incubated at RT until colonies started to detach slightly from the plate, EDTA was aspirated, 
new medium was added, and cells were scraped from the plate with a pipet tip, after which the cells 
were transferred to a new plate in a desired dilution.  
All cells were kept in Forma Steri-Cycle CO2 Incubator (Thermo Scientific) at +37 °C 
with 5 % CO2. 
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3.4. Transfection 
 
Cells were transfected by electroporation using NeonTM Transfection System (Invitrogen) according 
to the user manual. When electroporating lymphoblastoid cells, the culture was split to 0.5 * 106 
cells/ml density on the previous day to obtain optimal cell growth phase. 2 * 106 cells and 6 μg of 
total DNA were used for one electroporation with a 100 μl tip. Electroporation conditions for 
lymphoblastoid cells were 1300 V, 10 ms and 3 pulses using the R buffer from the NeonTM 
Transfection System Kit (Invitrogen, MPK10096).  
 Fibroblasts were detached from the plate with TrypLETM treatment as in passaging. 1 
* 106 cells and 6 μg of total DNA were used for one electroporation with a 100 μl tip. Electroporation 
conditions were 1650 V, 10 ms, 3 pulses with R buffer. 
 
3.5. FACS 
 
Fluorescence-activated cell sorting (FACS) samples were prepared as follows: 1 ml of cell suspension 
was transferred to a microcentrifuge tube, centrifuged 200 g, 5 min, at RT (LaboGene, ScanSpeed 
Mini), and the cell pellet was re-suspended to 500 μl of FACS-buffer (PBS (Sigma, D8537), 5 % FBS 
(Life Technologies, 10270-106)). FACS samples were filtered through a 30 μm filter to obtain a single 
cell suspension. Samples were run with BD FACSCaliburTM (BD Biosciences) and results analyzed with 
FlowJo® software. 
 
3.6. Reprogramming and iPSC line propagation 
 
To reprogram LCLs, the cells were transfected with reprogramming plasmid combinations. After 
transfection, cells were put to 6-well plates with hES + NaB medium (KnockOut DMEM (Life 
Technologies, 10829018), 20% KO serum replacement (Life Technologies, 10828028), 1% 
GlutaMAXTM (Life Technologies, 35050-038), 0.1 mM b-mercaptoethanol (Life Technologies, 31350-
010), 1% nonessential amino acids (Life Technologies, 11140050), 6 ng/ml basic fibroblast growth 
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factor (bFGF; Sigma, SRP4037), 0.25 mM sodium butyrate (NaB; Sigma-Aldrich, B5887)) for 
expansion, before transferring them to 10 cm MG plates for seeding. Cells were grown in hES + NaB 
medium until first iPSC colonies appeared, at which point the medium was changed to E8. Medium 
was changed every other day, first by centrifugation similarly to LCL culture, and once enough cells 
were attached to the plate, old medium was aspirated along with non-attached cells, and new 
medium was added. Cells were grown until the formed iPSC colonies were big enough for either 
alkaline phosphatase staining or iPSC line propagation, in any case up to maximum of 33 days. 
For iPSC line propagation, iPSC colonies were manually picked by cutting a colony to 
smaller pieces with a scalpel (Feather, M03E/5203012) and transferring the colony fragments with 
a pipet to MG coated 24-well plates in E8 medium. Clones from one LCL were picked from different 
iPSC colonies. From a 24-well plate, clones were transferred to 6-well plates and cultured as iPSCs. 
Clones were passaged up to 10 times to obtain enough cells for iPSC line characterization samples, 
before freezing two vials of each clone. 
 
3.7. Alkaline Phosphatase Staining 
 
Alkaline phosphatase (AP) staining was performed as follows: reprogramming culture plates were 
fixed with 4 % paraformaldehyde (PFA; Fisher Chemical, 10131580) for 10 min, RT. Plates were 
washed three times with PBS, and stained with NBT/BCIP containing solution (200 μl NBT/BCIP Stock 
Solution (Roche, 11681451001) in 10 ml 0.1 M Tris-HCl pH 9.5, 0.1 M NaCl, 0.05 M MgCl2) until AP 
activity was detected as precipitate development. Plates were washed with PBS to stop the reaction 
and scanned with Epson Perfection V500 Photo -scanner with 600 dpi resolution. The number of AP 
positive colonies was calculated manually from scanned images. Reprogramming efficiency was 
calculated as follows: !"	$%&'(')*	+%,%-'*&./0-&1*+(*2	+*,,& ∗ 100	%. 
 
3.8. Immunocytochemistry 
 
Cell culture samples for immunocytochemistry (ICC) were fixed with 4 % PFA for 30 min, RT. Cells 
were washed three times with PBS, and then permeabilized with PBS containing 0.2 % Triton-X 100 
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(Fisher Scientific, BP151-100) for 15 min, RT. Cells were washed again three times with PBS, and 
blocked with Ultra Vision protein block (Thermo Scientific, TA-125-PBQ) 10 min, RT. Blocking 
solution was aspirated and primary antibody mixture added. All antibodies were diluted in PBS with 
0.1 % Tween20 (VWR International, 663684B). Primary antibodies were incubated for 48 h when 
staining for pluripotency markers, or for 24 h when staining for germ layer markers, at +6 °C on a 
See-saw rocker (Stuart, SSL4) with the given dilutions. After primary antibody incubation, cells were 
washed three times with PBS and secondary antibody mixture was added. Secondary antibodies 
were incubated for 30 min, RT, on a See-saw rocker. Secondary antibody mixtures contained 10 
ng/μl Hoechst33342 (Sigma-Aldrich, B2261) to stain the nuclei. Used antibodies and dilutions in 
tables 2 and 3. Cells were imaged with EVOS FL microscope (Life Technologies). 
 
Table 2. Primary antibodies for pluripotency staining 
Antibody Host species Dilution Manufacturer Product code 
Oct3/4 Rabbit 1:500 Santa Cruz Biotechnology SC-9081 
Sox2 Rabbit 1:500 Cell Signaling 3579 
Lin28 Rabbit 1:500 Cell Signaling 8641 
Tra-1-60 Mouse 1:200 Thermo Scientific MA1-023 
Tra-1-81 Mouse 1:250 Thermo Scientific MA1-024 
Sox17 Goat 1:400 R&D Systems AF1924 
a-smooth muscle actin Mouse 1:400 Sigma A2547 
b-tubulin III Rabbit 1:500 Abcam Ab18207 
 
 
Table 3. Secondary antibodies 
Antibody Host species Dilution Manufacturer Product code 
Anti-Goat IgG (H+L) Alexa Fluor 488 Donkey 1:500 Invitrogen A-11055 
Anti-Mouse IgG (H+L) Alexa Fluor 488 Donkey 1:500 Invitrogen A-21202 
Anti-Mouse IgG (H+L) Alexa Fluor 594 Donkey 1:500 Invitrogen A-21203 
Anti-Rabbit IgG (H+L) Alexa Fluor 488 Donkey 1:500 Invitrogen A-21206 
Anti-Rabbit IgG (H+L) Alexa Fluor 594 Donkey 1:500 Invitrogen A-21207 
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3.9. RT-qPCR 
 
RNA samples for reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) were 
collected as follows: iPSCs and fibroblasts were detached from the plate by scraping with a pipet 
tip, transferred to a microcentrifuge tube, centrifuged at 200 g, 5 min, RT, and medium was carefully 
aspirated. Lymphoblastoid cells were just transferred to microcentrifuge tubes and treated similarly 
from there-on. Cell pellets were re-suspended to 350 μl of LBP lysis buffer from NucleoSpin® RNA 
Plus kit (Macherey-Nagel, 740984). RNA was purified with the NucleoSpin® RNA Plus kit, and the 
concentration was measured with SimpliNanoTM Spectrophotometer. RNA samples were 
concentrated when necessary with the Eppendorf Concentrator 5301.  
800 ng of total RNA was used for one reverse transcriptase (RTase) reaction in 11.3 μl 
of Nuclease free H2O, AccuGENETM Molecular Biology water (DEPC water; Lonza, 51200), which was 
heated at +65 °C for 1 min to get rid of any secondary structure. RTase reaction master mix was 
prepared per one reaction as follows: 
 4 μl M-MLV Reverse Transcription 5x buffer (Promega, M531A) 
 2.5 μl 2.5 mM dNTPs (Promega, U1420) 
1 μl Oligo(dT)18 primer (Thermo Scientific, SO132) 
0.2 μl Random primers (Promega, C118A) 
0.5 μl RiboLock RNase inhibitor (Thermo Scientific, EO0381) 
0.5 μl  M-MLV Reverse Transcriptase (Promega, M170A) 
 
8.7 μl of master mix was added to 11.3 μl RNA + DEPC water. Mixtures were vortexed well and spun 
down, before incubation at +37 °C, 90 min. The RTase was inactivated by incubating at +95 °C, 5 
min, and 20 μl of DEPC water was added. A water control was used to ensure contamination-free 
reagents. 
 For qPCR reactions, a master mix containing 5x HOT FIREPol EvaGreen qPCR Mix Plus 
(Solis BioDyne, 08-25-0020) and DEPC water was prepared and divided to PCR strips containing the 
cDNA. 2 uM forward and reverse primer mixes (table 4) were prepared. QiAgility pipetting robot 
(Qiagen) pipetted the reactions of 20 ul in duplicates as follows: 
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4 ul 5x HOT FIREPol EvaGreen qPCR Mix Plus 
 5 ul 2 uM F/R primer mix 
 1 ul cDNA 
 10 ul DEPC water 
 
qPCR was run with Qiagen Rotor-Gene Q or Rotor-Gene 6000 machine with the following program: 
Polymerase activation, initial denaturation 95 °C 15 min 
40 cycles: Denaturation  95 °C 25 sec 
  Annealing   57 °C 25 sec 
  Elongation   72 °C 25 sec 
 
Table 4. Primers for qPCR 
Gene Origin Forward primer1 Reverse primer1 Product 
length 
OCT4  human 
(NM_002701) 
5’-TTG GGC TCG AGA 
AGG ATG TG-3’   
5’-GTG AAG TGA GGG 
CTC CCA TA-3’   
193 bp 
SOX2  human 
(NM_003106) 
5’-GCC CTG CAG TAC 
AAC TCC AT-3’ 
5’-TGC CCT GCT GCG 
AGT AGG A-3’     
85 bp 
NANOG  human 
(NM_024865.2) 
F 5’-CTC AGC CTC CAG 
CAG ATG C-3’ 
5’-TAG ATT TCA TTC TCT 
GGT TCT GG-3’ 
94 bp 
REX1  human 
(NM_174900.3) 
5’-CGT TTC GTG TGT CCC 
TTT CAA-3’ 
5’-CCT CTT GTT CAT TCT 
TGT TCG T-3’ 
106 bp 
TDGF1  human 
(NM_003212.2) 
5’-TCA GAG ATG ACA 
GCA TTT GGC-3’ 
5’-TTC AGG CAG CAG 
GTT CTG TTT A-3’ 
118 bp 
Cyclophilin 
G 
human 
(NM_004792) 
5’-CAA TGG CCA ACA 
GAG GGA AG-3’      
5’-CCA AAA ACA ACA 
TGA TGC CCA-3’     
94 bp 
KLF4  human 
(NM_004235.4) 
5’-CCG CTC CAT TAC CAA 
G-3’ 
5’-CAC GAT CGT CTT CCC 
CTC TT-3’ 
80 bp 
CMYC  human 
(NM_002467) 
5’-AGC GAC TCT GAG 
GAG GAA CA-3’ 
5’-CTC TGA CCT TTT GCC 
AGG AG-3’ 
87 bp 
LIN28  human 
(NM_024674) 
5’-AGG AGA CAG GTG 
CTA CAA CTG-3’ 
5’-TCT TGG GCT GGG 
GTG GCA G-3’ 
74 bp 
1) Primers recognize endogenous and transgenic mRNAs. All primers ordered from Sigma. 
 
 The results were analyzed with the comparative Ct method (DDCt), normalizing the 
target Ct to a housekeeping gene (Cyclophilin G) and relative to a calibrator standard, and calculated 
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with 2-DDCt. For statistics, error bars were presented as standard error of the mean (SEM), and p 
values were calculated with one-way ANOVA and Dunnett’s multiple comparisons test as well as 
unpaired t test, where p < 0.05 was used as the statistical significance. Statistics were calculated 
using the GraphPad Prism 7 software. 
 
3.10. Embryoid Body Assay 
 
To initiate embryoid body (EB) formation, cells were treated with 0.5 mM EDTA, then scraped of the 
culture dish with a pipet tip and transferred to ultra-low attachment dishes (Corning, 3471) in hES 
medium without bFGF (KnockOut DMEM (Life Technologies, 10829018), 20% KO serum 
replacement (Life Technologies, 10828028), 1% GlutaMAX (Life Technologies, 35050-038), 0.1 mM 
β-mercaptoethanol (Life Technologies, 31350-010), 1% nonessential amino acids (Life Technologies, 
11140050)) supplemented overnight with 5 µM Rho-associated protein kinase (ROCK) inhibitor (Y-
27632; Selleckchem, S1049) to help cell survival. Medium was changed every other day by 
centrifugation (200 g, 5 min, RT), and suspending EBs to new medium. New medium was added 
every other day. EB clusters were disrupted by pipetting or by cutting with a scalpel. EBs were grown 
in suspension for 2 to 4 weeks and plated to cell culture dishes coated with 0.1 % gelatin (Sigma, 
G1890), where they were cultivated until enough outgrowth had formed for immunocytochemistry 
to detect germ layer markers. 
One third of the EBs were transferred to grow in fibroblast medium 5 days after 
initiating the EB formation to direct differentiation towards endodermal cell types, and these EBs 
were treated similarly to the ones in hES without bFGF. 
 
3.11. PCR for episome detection 
 
DNA samples for PCR detection of residual reprogramming and immortalization episomes were 
collected as follows: cells were detached from the plate by scraping with a pipet tip, transferred to 
a microcentrifuge tube, centrifuged at 200 g, 5 min, RT, and cell pellet was stored to -80 °C. To obtain 
DNA from collected cell pellets, the pellets were lysed by adding 100 μl DirectPCR Lysis Reagent 
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(Viagen, 302-C) with 1 μg/μl proteinase K (Macherey-Nagel, 740506), and incubating them in 55 °C, 
overnight, in a rotating Shake ‘n’ Stack Hybridization Oven (Hybaid). Lysis mixture was ready to use 
after inactivation by incubating in 85 °C for 1 hour. PCR reaction mixtures were prepared per one 
reaction (à 20 μl) as follows:  
4 μl   5X Phusion HF green buffer (Thermo Scientific, F-534) 
1.6 μl  2.5 mM dNTPs (Promega, U1420) 
0.2 μl  100 % DMSO (Thermo Scientific, F-534) 
1 μl  10 μM forward primer 
1 μl  10 μM reverse primer 
0.2 μl  2U/μl Phusion DNA Pol (Thermo Scientific, F-534) 
4 μl   5 M Betaine (Fluka, 14300) 
7.5 μl  H2O (Lonza, 51200) 
0.5 μl  DNA from lysis mixture  
 
iPSC lines were assayed for OriP, EBNA-1 and dCas9 genes, and GAPDH was used as an 
internal control to ensure that all samples contained genomic DNA. pCXLE-dCas9VP192-GFP-shp53 
plasmid was used as a positive control for EBNA-1, OriP and dCas9 at 0.2 ng/μl concentration. DNA 
samples from all the lymphoblastoid cell lines were used as controls. Since the LCLs had been 
immortalized with EBV, they should contain EBV-related genes, i.e. OriP and EBNA-1. HFF sample 
was used as a negative control. Primers used in episome PCR are listed in table 5. 
 
Table 5. Primers for episome detection PCR. 
Gene Forward primer1 Reverse primer1 Product 
length 
OriP pEP4-SF1-oriP  
5’-TTC CAC GAG GGT AGT GAA CC-3’ 
pEP4-SR1-oriP  
5’-TCG GGG GTG TTA GAG ACA AC-3’ 
544 bp 
EBNA-1 pEP4-SF2-oriP  
5’-ATC GTC AAA GCT GCA CAC AG-3’ 
pEP4-SR2-oriP 
5’-CCC AGG AGT CCC AGT AGT CA-3’ 
666 bp 
dCas9 Cas9_F1 
5’-AAA CAG CAG ATT CGC CTG GA-3’ 
Cas9_R2 
5’-CTG TCT GCA CCT CGG TCT TT-3’ 
1934 
bp 
GAPDH GAPDH h-m F1 sg 
5’-AAG AAG GTG GTG AAG CAG GC-
3’ 
GAPDH h-m R1 sg 
5’-CAG GAA ATG AGC TTG ACA AAG-
3’ 
164 bp 
1) Primers ordered from Sigma.  
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PCRs were run according to following programs: 
OriP and EBNA-1 
Initial denaturation  98 °C 3 min 
8 cycles: Denaturation  98 °C 10 sec 
 Annealing (down 0.5 °C/cycle) 66 – 62 °C 30 sec 
 Elongation   72 °C 20 sec 
30 cycles: Denaturation  98 °C 10 sec 
 Annealing   62 °C 30 sec 
 Elongation   72 °C 20 sec 
 Final elongation  72 °C 8 min 
 
GAPDH 
Initial denaturation  98 °C 3 min 
8 cycles: Denaturation  98 °C 10 sec 
 Annealing (down 0.5 °C/cycle) 65 – 61 °C 30 sec 
 Elongation   72 °C 7 sec 
30 cycles: Denaturation  98 °C 10 sec 
 Annealing   61 °C 30 sec 
 Elongation   72 °C 7 sec 
 Final elongation  72 °C 8 min 
 
dCas9 
Initial denaturation  98 °C 3 min 
8 cycles: Denaturation  98 °C 10 sec 
 Annealing (down 0.5 °C/cycle) 68 – 64 °C 30 sec 
 Elongation   72 °C 1 min 
30 cycles: Denaturation  98 °C 10 sec 
 Annealing   64 °C 30 sec 
 Elongation   72 °C 1 min 
 Final elongation  72 °C 8 min 
 
Annealing temperatures were calculated with the New England Biolabs web-based Tm 
Calculator (NEB 2017). 
PCR products for OriP, EBNA-1 and GAPDH were run in 1.0 – 1.5 % agarose (Fisher 
Bioreagents, 10766834) Tris/Borate/EDTA (TBE; Life Technologies, 15581044) gel, supplemented 
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with Midori Green Advance (NIPPON Genetics Europe, MG04), and PCR products for dCas9 were 
run in 1.0 – 1.2 % agarose Tris/Acetate/EDTA (TAE; Fisher Bioreagents, B1335-1) gel, supplemented 
with Midori Green Advance. GeneRulerTM 1 kb Plus DNA Ladder (Thermo Scientific) was used as the 
molecular ladder. Gels were imaged with Bio-Rad Gel DocTM XR+ System and Image LabTM Software. 
 
3.12. iPSC freezing 
 
iPSC lines were frozen as follows: cells were detached from plates with similar EDTA treatment as 
in passaging, and cells were scraped with a cell scraper and 500 μl of Freezing medium I (DMEM 
(Sigma, D6546), 20 % FBS (Life Technologies, 10270-106)), and transferred to a freezing vial (Fisher 
Scientific, 12-567-501). 500 μl of cold Freezing medium II (DMEM (Sigma, D6546), 20 % FBS (Life 
Technologies, 10270-106), 20 % DMSO (Sigma, D2650)) was added drop-wise, and the cells and 
media were mixed by turning the vial a few times. Vials were stored to -80 °C in styrofoam freezing 
boxes for initial freezing, and then transferred to -150 °C for long-time storage. 
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4. Results 
 
4.1. Selection of lymphoblastoid cell line for CRISPRa mediated reprogramming 
 
The CRISPRa mediated reprogramming method established in HFFs had had a lower reprogramming 
efficiency than the transgenic system. For this reason, it was important to select an LCL with the 
highest possible reprogramming efficiency for the first CRISPRa reprogramming experiments. To 
determine which LCL had the highest reprogramming efficiency, all cell lines were reprogrammed 
with transgenic reprogramming factors. LCL IB-D5 gave rise to the highest number of iPSC colonies, 
quantified by AP staining (figure 1). To determine whether the transfection efficiency of the LCLs 
caused the variability in the reprogramming efficiencies, a transfection efficiency assay was 
performed. All LCLs were transfected with a GFP plasmid, and three days later the percentage of 
GFP positive cells was determined with FACS. The percentage was used as a direct indicator of the 
transfection efficiency. All cell lines had similar transfection efficiencies between 55 – 80 %, and no 
correlation between the reprogramming and transfection efficiency was detected, with R2 = 5,7*10-
5 (figure 1). This suggested that the cell lines had different reprogramming efficiencies, and as IB-D5 
had the highest efficiency, it was selected for the first reprogramming experiments. 
 
 
Figure 1. Transfection versus reprogramming efficiencies of the six LCLs. Linear trend line drawn in 
black. Data from two individual experiments, N = 1 for both experiments. 
R2 = 5,7 * 10-5 
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4.2. CRISPRa mediated reprogramming of IB-D5 
 
Since LCLs had never been reprogrammed using the CRISPRa system, seven different gRNA 
combinations were tested to see if they would be able to reprogram the cells. Each CRISPRa 
combination included the dCas9-VP192 activator with shp53 and gRNAs targeting the promoter 
regions of reprogramming factors OCT4, SOX2, KLF4, C-MYC and LIN28 (OSKML), on top of which 
additional gRNAs for REX1, NANOG, LIN28 and the EEA-motif (either 1 or 5 guides) were assayed 
(table 6). Transgenic GFP was used as the negative control and a combination of transgenic OCT4, 
SOX2, KLF4, L-MYC and LIN28 with shp53 as the positive control. 
 
 
 
LCL IB-D5 was transfected with the seven CRISPRa combinations and the controls, and 
the cells were grown as described in the figure 2. The emerged iPSC colonies were recognized based 
on morphology and the number of iPSC colonies was quantified with AP staining (figure 2).  
Table 6. CRISPRa combinations and controls
Combination Transgenes Guide-RNAs1
OSKML R N L E1 E5
CRISPRa2
G GFP x
E1 x x
E5 x x
RN x x x
RNE1 x x x x
RNE5 x x x x
NLE5 x x x x
Controls
Negative GFP
Transgenic OCT4, SOX2, KLF4, 
L-MYC, LIN28, shp53
1) Guide-RNAs targeting the promoter regions of the endogenous genes
2) All CRISPRa combinations included the dCas9-VP192 activator and shp53
OSKML = OCT4, SOX2, KLF4, C-MYC, LIN28, R = REX1, N = NANOG, L = LIN28, E1 = one guide 
for EEA motif, E5 = five guides for EEA motif
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Figure 2. Reprogramming of lymphoblastoid cell lines. iPSC = induced pluripotent stem cell, AP = 
alkaline phosphatase, MG = matrigel, LCLs = lymphoblastoid cell lines 
 
Three CRISPRa combinations, which all included the targeting of the EEA-motif, gave 
rise to iPSC colonies (figure 3). Combination of guides for OSKML with REX1, NANOG and one guide 
for the EEA motif (RNE1) gave rise to the highest number of iPSC colonies. However, the efficiency 
was low with the mean efficiency of 0.00018 % from three inductions for combination RNE1 
compared to the transgenic 0.00543 % from two inductions. 
 
 
Figure 3. Number of AP positive colonies yielded from reprogramming of IB-D5 with reprogramming 
plasmid combinations. Data from three individual experiments, combination NLE5, the negative 
control and the transgenic (TG) control were not included in the first experiment. 
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4.3. Guide-RNA function validation 
 
Because of the low reprogramming efficiency, a gRNA function validation assay was performed to 
determine whether the used gRNAs were able to induce the gene expression of the targeted genes 
in LCLs. IB-D5 was transfected with the CRISPRa combinations, and after four days, the expression 
levels of the targeted genes were analyzed with RT-qPCR. The expression levels elicited by the 
CRISPRa combinations showed a consistent trend of activation compared to the negative control 
for all targeted genes, except for LIN28 (figure 4). However, there were only a few statistically 
significant gene activation levels, determined by One-way ANOVA and Dunnett’s multiple 
comparisons test between the CRISPRa combinations and the negative control. 
 The gRNA function validation assay also showed whether the gene expression levels 
of OCT4, SOX2, KLF4 and LIN28 elicited by the CRISPRa combinations were similar to those in the 
transgenic control. OCT4 was expressed similarly with both CRISPRa and transgenic systems, and no 
statistical significance was found between the CRISPRa combinations and the transgenic control, 
determined by One-way ANOVA and Dunnett’s multiple comparisons test. This suggested that the 
CRISPRa system can elicit as high gene expression levels as the transgenic system. However, the 
expression levels for SOX2, KLF4 and LIN28 were much higher in the transgenic control (P < 0.0005, 
P < 0.0001, P < 0.0001 respectively for all comparisons) potentially explaining the generally low 
reprogramming efficiency of the CRISPRa system. 
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Figure 4. Relative expression of the CRISPRa targeted genes in IB-D5 on day 4 after transfection with 
the reprogramming combinations. Transgenic control does not include C-MYC, NANOG or REX1. 
Expression levels presented as a fold change, normalized to negative control. Error bars represent 
SEM. Statistical significance between the CRISPRa combinations and the negative control 
determined with ordinary one-way ANOVA and Dunnett’s multiple comparisons test. * P < 0.05. N 
= 3. 
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Since this was the first time the CRISPRa reprogramming was established in LCLs, there 
were no LCL models which could have been used as the positive control to show the necessary gene 
activation by CRISPRa for efficient reprogramming. For this reason, the CRISPRa elicited gene 
expression levels in IB-D5 were compared to those in HFFs, in which the CRISPRa reprogramming 
had already been successfully established with the same gRNAs (Weltner et al. 2018). The gRNA 
function validation assay was performed in HFFs alongside IB-D5 with the negative and positive 
controls and the combination RNE1. RNE1 was selected because it gave rise to the highest number 
of iPSC colonies in IB-D5 in the reprogramming experiment and elicited the highest expression of 
NANOG and REX1. 
None of the genes were significantly upregulated or downregulated by the CRISPRa 
system in HFFs compared to the negative control, determined with a two-way t test (figure 5). Since 
the assay could only be performed twice in HFFs, the statistical significance was affected. These 
results, nevertheless, showed similar activation trends for OCT4, SOX2, LIN28, NANOG and REX1, 
while it seems that in HFFs the CRISPRa system rather repressed the expression of KLF4 than 
activated it as in IB-D5. However, KLF4 had high expression already in control HFFs, which might 
affect the activation levels. C-MYC seemed to be unaffected by the CRISPRa combination. None of 
the genes, which were targeted by CRISPRa and included in the transgenic control, were activated 
with the CRISPRa system to the same level as they were expressed in the transgenic control. 
However, no statistical significance between the expression levels of the genes activated by the 
CRISPRa system and expressed by the transgenic control was found, most likely due to the number 
of replications. 
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Figure 5. Relative gene expression of the CRISPRa targeted genes in HFFs four days after transfection 
with combination RNE1 and the controls. Expression levels presented as a fold change, normalized 
to the negative control. Error bars represent SEM. No statistical significance was found between the 
expression levels between RNE1 and negative control or between RNE1 and transgenic control, 
determined with a two-way t test. N = 2. 
 
To compare the expression levels elicited by the CRISPRa system in IB-D5 and HFFs, 
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types had been transfected with similar efficiencies. OCT4 was expressed at similar levels 
endogenously in the negative controls in both cell types, indicating that differences in the 
expression levels of OCT4 in the transgenic control would result from different transfection 
efficiencies between the cell lines. The OCT4 expression was similar in both cell types (figure 6), 
which suggested that the cell types had been transfected similarly, and that the gene expression 
levels elicited by the CRISPRa combination RNE1 could be compared. 
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Figure 6. Relative expression of OCT4 in the transgenic control in IB-D5 and HFFs four days after 
transfection. Expression levels presented as a fold change, normalized to the negative control in IB-
D5. Error bars represent SEM. P = 0.8540, determined by a two-way t test. N = 3 for IB-D5, N = 2 for 
HFF. 
 
There was no statistical significance between the expression levels of OCT4, SOX2, 
LIN28, C-MYC or NANOG elicited by the CRISPRa combination in IB-D5 and HFFs, determined with a 
two-way t test (figure 7). However, the gene expression levels of KLF4 and REX1 were significantly 
higher in HFFs than in IB-D5. 
 
 
Figure 7. Relative gene expression levels of the CRISPRa targeted genes in IB-D5 and HFFs four days 
after transfection with the combination RNE1. Expression levels expressed as fold change, 
normalized to the negative control in IB-D5. Error bars represent SEM. Statistical significance 
determined with a two-way t test. * P < 0.05. N = 3 for IB-D5, N = 2 for HFFs. 
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Overall, these results suggest that the gRNAs were suboptimal for efficient expression 
of some of the targeted genes, such as KLF4 and LIN28, in IB-D5. It also seems that some of the 
gRNAs, for example the ones for REX1, function better in HFFs. 
 
4.3. Derivation and characterization of iPSC lines from five LCLs 
 
Based on the results from the CRISPRa reprogramming experiment and the gRNA function validation 
assay, combination RNE1 was selected as the best for reprogramming of LCL IB-D5. To see whether 
it would also reprogram other LCLs, all six LCLs were transfected with the combination. After first 
induction, only three LCLs generated iPSC colonies (figure 8). The induction was repeated for all 
lines, and on the second time five LCLs gave rise to iPSC colonies. IB-D3 was included only in the 
second induction set due to low proliferation rate. There was a high variability in reprogramming 
efficiencies, and for example IB-D2 did not yield any iPSC colonies in the first induction, while in the 
second induction it had the highest reprogramming efficiency, giving rise to over 650 iPSC colonies. 
 
 
Figure 8. Number of AP positive colonies from two induction sets of the six LCLs, reprogrammed 
with CRISPRa combination RNE1. IB-D3 was included only in the second induction set. 
  
To prove that the CRISPRa system was able to reprogram LCLs into bona fide iPSCs, 
three iPSC line clones of each LCL, except for IB-D3, were derived, named and characterized 
according to table 7. Lines were characterized with basic characterization standards, and one clone 
of each established iPSC line was characterized with all the assays. 
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Table 7. Characterization of LCL derived iPSC lines.
iPSC 
line
LCL
Clone
PP 
ICC
1
PP m
arkerICC
PP RT-
qPCR
1
EB 
assay
1
EB germ
 layer m
arkerICC
Episom
e 
gene 
PCR
1
ID PCR
1
Oct4 + 
Tra-1-60
Lin28 + 
Tra-1-81
Sox2 + 
Tra-1-81
⍺-SM
A
TUBB3
SOX17
HEL159
IB-D6
3
3
x
x
9
3
x
x
x
5
4
6
3
x
x
8
3
x
x
x
5
4
9
3
x
x
8
3
x
x
x
5
4
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IB-D2
4
3
x
x
10
6
x
x
x
4
7
12
4
x
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x
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3
16
3
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x
6
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4
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15
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All iPSC clones resembled ESCs morphologically: the cells were small, they formed 
tightly packed, round colonies with distinct borders, and had a high nucleus/cytosol ratio. All clones 
were stained with ICC for pluripotency stem cell markers OCT4, TRA-1-60, TRA-1-81, and LIN28 or 
SOX2 (figures 9 and S1).  
 
Figure 9. Pluripotency marker expression of 5 iPSC line clones assayed with ICC for OCT4, TRA-1-60, 
TRA-1-81, and LIN28 or SOX2. Nuclei stained with Hoechst33342. Scale bar = 200 µm. 
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All assayed clones were positive for the expression of pluripotency marker genes 
OCT4, SOX2, NANOG, REX1 and TDGF1, analyzed also with RT-qPCR (figure 10). OCT4 and NANOG 
were expressed consistently at a lower level in LCL-derived iPSCs compared to the HEL46.11 iPSC 
control. SOX2 expression, on the other hand, was slightly higher in all the LCL-derived iPSCs. REX1 
and TDGF1 expression levels were similar to the ones in HEL46.11. 
 
 
Figure 10. Relative expression of pluripotency markers OCT4, SOX2, NANOG, REX1 and TDGF1 in 10 
LCL-derived iPSC lines analyzed with RT-qPCR. Expression levels are normalized to the HEL46.11 
(p38) iPSC control, HFF used as a negative sample. N = 1 of each line. 
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The iPSC clones were analyzed for any residual reprogramming plasmids with PCR for 
dCas9, OriP, EBNA-1 and GAPDH genes (figure 11). 11 out of 15 iPSC clones were negative for dCas9. 
The absence of dCas9 suggests that the endogenous pluripotency network had stabilized in the cells, 
since no dCas9 mediated reprogramming gene activation could occur. Out of the four positive lines, 
the faint band in HEL162.4 suggests that only a portion of the cells in the sample contained the 
activator plasmid. HEL160.4, HEL162.4 and HEL163.11, however, gave quite intense bands for 
dCas9, meaning that the cells still contained transgenic plasmid sequences. 
13 out of 15 iPSC clones and all five LCLs were positive for EBNA-1 and OriP. Since the 
LCLs had been immortalized with EBV, it was expected that they would give bands, and it might be 
that the EBNA-1 and OriP positive iPSC clones were still harboring the immortalization plasmids. The 
bands for EBNA-1 and OriP from iPSC clones might have also come from the gRNA reprogramming 
plasmids, and the bands in the dCas9 positive clones were at least partly due to the activator 
plasmid. In each cell line, the strongest band came from the LCL sample, indicating that the 
immortalization and reprogramming plasmids have been at least partially diluted out of the derived 
iPSC clones. HEL160.12 and HEL161.17 seem to have lost all episomes. 
GAPDH showed similar levels of genomic DNA in all cellular samples. 
 
 
Figure 11. PCR for dCas9, EBNA-1, OriP and GAPDH of LCL-derived iPSC lines. L = parental LCL, H = 
HFF control, P = activator plasmid control, W = water control. 
 
To see whether the generated iPSC lines were able to differentiate to all three germ 
cell layers, an embryoid body assay was performed to 12 out of 15 clones. A clear signal of tri-lineage 
differentiation was detected from 9 out of 12 clones with ICC (figures 12 and S2). 
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Figure 12. ICC shows clear signal of tri-lineage differentiation of 5 iPSC clones derived from different 
LCLs. Smooth muscle actin (a-SMA) was used as a mesendodermal marker, SOX17 as a endodermal 
marker, and b-tubulin (TUBB3) as an ectodermal marker. Nuclei stained with Hoechst33342. Scale 
bar = 200 µm. 
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All lines were genotyped for the D1S80 locus to confirm iPSC line identity. Each iPSC 
clone matched its parental LCL (figure 13). HEL161 and HEL160 had the same allele of the locus, and 
additional loci should be genotyped in order to verify that no mixing of the clones had occurred. 
Also, the genotyping showed that HEL163 (LCL IB-D5) might harbor a chromosomal abnormality, 
since it showed three bands of the allele instead of two, which is the maximum number of bands 
from cells with normal karyotypes. Since the three bands are also present in the LCL sample, the 
possible mutation had not emerged during the reprogramming process. Karyotyping should be 
performed in order to identify the chromosome anomaly. 
 
 
Figure 13. Genotyping of iPSC clones and LCLs for the D1S80 locus. L = parental LCL. 
 
In conclusion, the CRISPRa mediated reprogramming was successfully established in 
five different LCLs and three bona fide iPSC clones of each LCL were derived. Two vials of each clone 
were frozen and returned to the THL biobank as a future research resource. 
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5. Discussion 
 
In order to utilize the vast LCL collections in biobanks and cell repositories more thoroughly, it is 
crucial to understand the cell specific events that take place in LCLs during the reprogramming 
process, and to this end the CRISPR/dCas platform has been applied. In this thesis project, the novel 
CRISPRa mediated reprogramming method was established for the first time in biobanked LCLs. The 
success of the established method was demonstrated by the reprogramming of five LCLs into bona 
fide iPSC lines. The reprogramming efficiencies were varying between experiments, and we showed 
that the gRNAs used in these experiments were suboptimal for efficient gene activation of some of 
the targeted genes in LCLs. These results also raised a question of the utility of LCLs in iPSC 
technology derived research, given the possible chromosomal aberration detected in one of the cell 
lines. This thesis work serves as the first stepping stone on the way to understand the events 
occurring in LCLs during reprogramming and to develop an LCL specific reprogramming method, 
which would result in better quality iPSCs and higher reprogramming efficiencies. 
 
5.1. CRISPRa reprogramming of LCLs 
 
The CRISPRa mediated reprogramming method was successfully employed to reprogram five out of 
six biobanked LCLs, demonstrated by the characterization of the derived iPSC lines. All clones met 
the standard characterization requirements but given the time and resource constraints, complete 
characterization could not be performed. The samples were collected at early passages, which might 
have impacted the detection of the residual episomal plasmids and the pluripotency marker 
expression levels. It is likely that that the reprogramming and immortalization plasmids would have 
been diluted out with further passaging, as previous studies have shown that LCL-derived iPSCs are 
free of EBNA-1 and OriP sequences by passage 20 (Barrett et al. 2014; Rajesh et al. 2011; Thomas et 
al. 2015). The cell lines which were positive for the episomal plasmid sequences should be passaged 
further and re-analyzed. Also, samples from later passages might have had more similar 
pluripotency gene expression levels as the HEL46.11 control from passage 38, since it has been 
shown that early and late passage iPSCs exhibit differential gene expression (Chin et al. 2012), and 
early passage iPSCs can still exhibit cell-type-of-origin-specific epigenetic modifications (Polo et al. 
 
 
 52 
2010). In the light of this, it would have been interesting to use an LCL-derived, transgenically 
reprogrammed, earlier passage iPSC line as a control for the characterization experiments, but due 
to resource constraints such cell lines could not be derived. To fully characterize the generated iPSC 
lines, the following assays should be performed (Martí et al. 2013): the lines should be karyotyped 
to confirm the genomic integrity; the lines should be genotyped with additional markers; and a 
pluritest should be performed to verify the pluripotent state of the cell lines in more detail. 
Even though the CRISPRa mediated reprogramming method was proven to 
successfully reprogram LCLs into bona fide iPSCs, the reprogramming efficiency was generally low 
and variable between experiments. The variation could be caused by several factors, such as the 
cell proliferation of the LCLs during electroporation, the success of the electroporation, handling of 
the cells during media change, and differences in the time period the cells were grown in hES and 
E8. The efficiency of transgenic LCL reprogramming has been improved by the optimization of the 
transfection and culturing protocols (Kumar et al. 2016), and a more optimized protocol could also 
improve the CRISPRa reprogramming efficiency and diminish the variation. However, since the 
generated iPSCs provide a perpetual source of self-renewing cells, the reprogramming method 
might not need to have the highest possible efficiency, if it produces high-quality iPSCs which can 
be expanded. 
 The functional assay for the CRISPRa system, i.e. the actual reprogramming of LCLs 
into iPSCs, proved that the CRISPRa system is capable of activating the necessary genes for 
successful reprogramming. However, the gRNA function validation assay showed that the gRNAs 
did not elicit as efficient gene activation of all targeted genes in LCLs as they did in fibroblasts, which 
might explain why the reprogramming efficiencies were low in LCLs. One of the factors that might 
more notably affect the reprogramming efficiency is the poor activation of KLF4, which has been 
shown to be important in B lymphocyte reprogramming (Wen et al. 2016; Di Stefano et al. 2016). 
Also, the LIN28 expression levels seemed to be unaffected by the CRISPRa system, but similar results 
have been obtained in previous studies (Weltner et al. 2018), where they showed with ICC that 
LIN28 is indeed expressed in some cells, but not detected in the RT-qPCR results due to the bulk 
effect of the sample. Similar staining assay should be performed to determine whether the low gene 
activation levels in these assays were also due to bulk effect. Most of the gene expression levels 
elicited by the CRISPRa system fell far from those of the transgenic system, except for OCT4. The 
high activation level of OCT4 demonstrated that it is possible to activate the endogenous gene 
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expression with the CRISPRa system to the same level as it is expressed in the transgenic system. 
However, it is not known whether the CRISPRa mediated reprogramming process requires the 
endogenous reprogramming factors to be expressed at the same level as they are expressed from 
the ectopic plasmids in transgenic reprogramming.  
Comparison between the expression levels of the targeted genes in LCLs and 
fibroblasts revealed that the CRISPRa system had different responses in different cell types, for 
example the elicited REX1 expression was higher in fibroblasts than in LCLs. This could be explained 
by different chromatin architecture in different cell types, which can make some target loci less 
accessible in LCLs. Interestingly, the targeting of KLF4 in fibroblasts seemed to downregulate its 
expression rather than upregulate it, though statistically the downregulation was not significant. 
Still, the expression level of KLF4 was some 20 times higher in fibroblasts compared to LCLs. This 
suggests that for fibroblasts, the activation of KLF4 is not as crucial as it might be for LCLs since the 
base level expression is already high enough. This goes along with findings showing that KLF4 poises 
B lymphocytes for efficient reprogramming (Di Stefano et al. 2016). Since the gRNA function 
validation could only be performed twice in fibroblasts, the trends detected from this experiment 
should be confirmed with additional replicates. It would have been interesting to fully reprogram 
fibroblasts with the CRISPRa system to see if the results from the gRNA function validation would 
be reciprocated in the number of emerged iPSC colonies. 
Based on the reprogramming experiments, the EEA motif targeting is crucial for the 
successful reprogramming of LCLs with the CRISPRa system. The importance of the EEA motif 
targeting was further supported by the gRNA function validation assay. Combinations G, E1 and E5 
elicited very similar gene expressions of all the targeted genes, yet the only one that gave rise to 
iPSCs in the functional assay was combination E5, which included five gRNAs for the EEA motif. Also, 
combination RN activated all targeted genes better than RNE5, which elicited the lowest expression 
of nearly all of the genes, but still out of the two, only RNE5 gave rise to iPSCs, highlighting the 
necessity of the EEA motif targeting. The EEA motif targeting has been shown to improve the 
activation of NANOG and REX1 when they are targeted by the CRISPRa in fibroblasts (Weltner et al. 
2018). The levels of NANOG and REX1 from combination RN and RNE1 support this, but RNE5, which 
theoretically should have the highest NANOG and REX1 levels, does not. This could be explained by 
too many EEA motif gRNA-dCas9 complexes interfering with the binding of the NANOG and REX1 
specific gRNA-dCas9 complexes. The expression levels of the other targeted genes were not affected 
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by the EEA motif targeting, suggesting that the importance of the motif targeting in LCLs does not 
result from facilitating the activation of these genes. It is possible that since LCLs are transformed 
from fully mature B lymphocytes, their silenced pluripotency associated loci require the additional 
opening, induced by the EEA motif targeting throughout the gene network related to EGA, for the 
endogenous reprogramming factors to be able to bind after they have been activated by the gRNA-
dCas9 complexes. Since the efficiencies in the first reprogramming experiment were quite low, it 
would be important to perform both the reprogramming as well as the gRNA function validation 
assays again simultaneously, in order to obtain more comparable results. 
 
5.2. The usability of LCLs in iPSC technology 
 
Previous records of LCL reprogramming have resulted in bona fide iPSCs with normal karyotypes 
and complete loss of the immortalization and reprogramming plasmids (Barrett et al. 2014; Rajesh 
et al. 2011; Thomas et al. 2015; Kumar et al. 2016; Son et al. 2017), and these kind of LCLs have been 
used for disease modeling (Fujimori et al. 2016). However, the results from the characterization 
assays raise the question whether all LCLs are safe to use in iPSC technology related research. The 
LCLs used in this study were obtained from THL biobank without information about their passage 
number or immortalization status. The genotyping assay revealed a potential chromosomal 
aberration in LCL IB-D5, which suggests that the cell line could have undergone immortalization, 
since immortalization has been previously shown to be usually accompanied by aneuploidy and 
other chromosomal mutations (Okubo et al. 2001). It is also possible that the other LCLs carry 
chromosomal mutations. Karyotyping would reveal the chromosomal state of the cell lines, and in 
the case of abnormal karyotypes, their effects on downstream applications should be considered. 
Also, if these LCLs are post-immortal, there is a chance that they are tumorigenic (Takahashi et al. 
2003). For the future development of the LCL reprogramming method, it should be considered 
whether it would be more beneficial to focus primarily on reprogramming pre-immortal LCLs, since 
they produce genetically integral iPSCs with wider downstream application possibilities. Pre-
immortal LCLs could also provide a more homogeneous starting material since chromosomal 
mutations could introduce changes to the reprogramming properties of post-immortal LCLs. 
However, biobanks might have not addressed the immortalization status of their LCLs, and 
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collections might include both pre- and post-immortal cell lines or only post-immortal ones, 
establishing the requirement for a reprogramming method for both types of LCLs. 
 The PCR for residual plasmids showed that 13 iPSC clones still had EBNA-1 and OriP 
sequences. Even though the episomal plasmids will most likely be diluted out of the cells with 
further passaging, there is a possibility that the EBV genome has been integrated into the host 
genome. If the episomal plasmids are not diluted out after 20 passages, the possible integration 
could be assayed with Southern blotting. There is no record of LCL-derived iPSCs with integrated 
EBV genome, so the potential effects of the integration to the iPSCs are not known. It has been 
shown that EBNA-1 is unable to activate the gene expression of integrated EBV related genes or 
host genes(Kang et al. 2001), which would suggest that the genome would not affect the gene 
expression of the host cell. However, in B lymphocytes, the integration of the viral genome in 
specific locus has been suggested to contribute to lymphomagenesis (Takakuwa et al. 2004). 
 LCLs have an advantage over fibroblasts as a reprogramming starting material, since 
they are cultured in suspension. As cells start to reprogram, they attach to the plate, making it easy 
to distinguish between the reprogrammable and non-reprogrammable cells in the culture. The non-
reprogrammable cells can be easily discarded during medium change. This offers a great possibility 
for more high-through-put reprogramming of the biobanked LCL collections, as the 
reprogrammable cells can be selected early in the process and culture without the disturbing effects 
of non-reprogrammable cells, possible resulting in higher yields.  
 
5.3. Future perspectives 
 
The fifteen iPSC line clones generated in this thesis project comprise the first ever iPSC line collection 
derived from THL biobank cells with the CRISPRa mediated reprogramming method and serve as 
the proof of concept that biobanked LCLs can be reprogrammed with the method, thus paving the 
way for the more thorough utilization of the vast LCL collections. The presented data serves as the 
starting point for the understanding of the reprogramming process and the development of more 
efficient reprogramming methods for LCLs. To improve the system, the next step would be to screen 
for additional factors that could improve the reprogramming efficiency, first transgenically and then 
design gRNAs for the best candidates. These additional factors could be C/EBPa, which is a B 
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lymphocyte specific reprogramming factor (Di Stefano et al. 2014), and factors which have been 
associated with the EEA motif (Weltner et al. 2018). Also, additional gRNAs for the genes already 
tested here could be designed and screened to see if the activation levels could be improved by 
targeting different sites in the promoter or even in the enhancer regions. To distinguish the best 
gRNAs for LCLs, a CRISPR based high-through-put screening system could be employed (Chen et al. 
2015; Doench 2018). 
 To understand the endogenous events required for reprogramming of LCLs, the effects 
elicited by the endogenous reprogramming factors should be studied on a single cell level. Gene 
expression changes occurring during transgenic reprogramming of LCLs have been studied with 
whole-genome RNA sequencing (Kumar et al. 2016), but since the induced cell population is 
heterogeneous, the events occurring in reprogrammable cells can be masked under the bulk effect. 
Also, in transgenic reprogramming the crucial endogenous events might be obscured under the 
stochastic, but reprogramming-wise unnecessary, events elicited by the transgenic factors. With 
single-cell RNA sequencing and the CRISPRa mediated reprogramming, the cell-type-specific 
reprogramming events could be studied in a single-cell level without any transgene influence. 
Another approach would be to study the chromatin accessibility and its changes during 
the reprogramming process in LCLs with Assay for Transposase Accessible Chromatin and high-
throughput sequencing (ATAC-seq). This could reveal the epigenetic changes required for the 
acquisition of pluripotent state, and chromatin remodeling complexes could be employed with the 
CRISPRa platform to assist in those changes. For example, the dCas9-SunTag-p300 system, which 
was used to remodel the endogenous Sox2 and Oct4 promoters to achieve reprogramming in mouse 
fibroblasts (Liu et al. 2018), could be applied also in human cells. The changes in the chromatin could 
also reveal more about the role of the EEA motif targeting, as its function has been hypothesized to 
facilitate chromatin accessibility. If the EEA motif has a similar time-dependent function as the LINE-
1 elements in regulating chromatin accessibility (Jachowicz et al. 2017), it would be interesting to 
study the effects of transient EEA motif targeting. It could be that that the EEA motif targeting is 
only required in the beginning of the reprogramming process to facilitate the initial chromatin 
opening and binding of the other gRNA-dCas9. 
 The CRISPRa mediated reprogramming method relies only on the activation of the 
endogenous reprogramming factor genes. However, there are several factors which impede the 
reprogramming process and could be repressed to improve the reprogramming efficiency (Ebrahimi 
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2015). To further develop the CRISPRa reprogramming method, the multiplexing capabilities of the 
CRISPR system could be utilized also to repress factors. The CRISPR platform offers the possibility to 
introduce the effector domains also fused to the gRNA (Mali, Esvelt, et al. 2013), which enables both 
repressing and activating gRNAs targeting different sets of genes to be used in the same cell. 
Another way to introduce both effects into a single cell is to utilize two dCas9 proteins from different 
species with different effector domains fused to them. As different origin Cas9s have different PAM 
site specificity (Kleinstiver et al. 2015), they could be used to target different set of genes. 
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8. Appendices 
 
8.1. Supplementary figures 
 
 
Supplementary figure 1. Pluripotency marker expression of rest of the iPSC line clones determined 
by ICC. The lines were positive for the expression of OCT4, TRA-1-60, TRA-1-81, and LIN28 or SOX2. 
Nuclei stained with Hoechst33342. Scale bar = 200 µm. 
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Supplementary figure 2. ICC shows clear signal of tri-lineage differentiation of 4 iPSC lines, and 
differentiation to one or two germ cell layers of 3 iPSC lines. Smooth muscle actin (a-SMA) was used 
as an mesendodermal marker, SOX17 as a endodermal marker, and b-tubulin (TUBB3) as an 
ectodermal marker. Nuclei stained with Hoechst33342. Scale bar = 200 µm. 
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